Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2018-02-06 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Cancer vaccine shows early promise in clinical trial 2 pages 240.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited reporting early clinical trial results for their cancer vaccine HER-Vaxx. It discusses clinical data, safety, immune responses, and dose escalation recommendations. The content is a company announcement about clinical trial progress and early data, not a full financial report, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just stating a report is available. The document is short (4024 characters) and focuses on clinical trial updates, which fits best under a general regulatory announcement category rather than financial or governance reports. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-02-06 English
Change in substantial holding 4 pages 164.6KB
Regulatory Filings
2018-02-05 English
Change in substantial holding 3 pages 95.1KB
Regulatory Filings
2018-02-05 English
Business Update - December Quarter Appendix 4C 7 pages 1.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Business Update – December Quarter Appendix 4C' and is described as a quarterly report for the quarter ended 31 December 2017. It includes detailed cash flow statements, financing activities, payments to directors, and estimated cash outflows for the next quarter. The document references compliance with Listing Rule 4.7B and Australian Accounting Standards related to cash flow statements. The content is substantive financial data for a period shorter than a full fiscal year (quarterly), including operating, investing, and financing cash flows, which aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification but contains actual financial statements and analysis for the quarter. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2018
2018-01-28 English
SF Biotech Presentation 34 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene Limited's immuno-oncology technology, specifically focusing on their mimotope induced B-cell antibodies and clinical trial phases for their HER-Vaxx therapy. It includes executive summaries, technology explanations, clinical trial designs, investigator information, and market opportunity. The content is structured as a presentation with slides, forward-looking statements, and detailed scientific and clinical data. There is no indication that this is an official regulatory filing, annual or interim report, earnings release, or any other formal financial or legal document. The presence of forward-looking statements and detailed company and product information aimed at investors strongly suggests this is an investor presentation.
2018-01-08 English
Change of Director's Interest Notice - CW 2 pages 135.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options held before and after the change, nature of the change, and value consideration. This type of document is a regulatory filing specifically reporting personal share transactions by company directors. It matches the definition of 'Director's Dealing' filings, which report insider trades by directors and executives. The document length is under 5,000 characters and contains detailed transaction data, not just an announcement or certification. Therefore, the correct classification is DIRS (Director's Dealing).
2017-12-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.